Research Article
Para-Aortic Lymph Node Dissection for Patients with Node-Negative Cervical Squamous Cell Carcinoma: A Retrospective Cohort Study
Table 1
Relationship between PALND and clinicopathological features before and after propensity score matching.
| | Variable | Before matching | After matching | | −PALND (N = 2095) | +PALND (N = 332) | value | −PALND (N = 313) | +PALND (N = 313) | value |
| | Age, years | | ≤47 | 1096 (52.3%) | 206 (62.0%) | 0.001 | 198 (63.3%) | 199 (63.6%) | 0.934 | | >47 | 999 (47.7%) | 126 (38.0%) | | 115 (36.7%) | 114 (36.4%) | | Menopausal status | | Premenopausal | 1377 (65.7%) | 248 (74.7%) | 0.001 | 234 (74.8%) | 235 (75.1%) | 0.927 | | Postmenopausal | 718 (34.3%) | 84 (25.3%) | | 79 (25.2%) | 78 (24.9%) | | FIGO stage | | IB | 1063 (50.7%) | 154 (46.4%) | 0.14 | 142 (45.4%) | 141 (45.0%) | 0.936 | | IIA | 1032 (49.3%) | 178 (53.6%) | | 171 (54.6%) | 172 (55.0%) | | Tumor diameter (cm) | | ≤4 | 1536 (73.3%) | 198 (59.6%) | <0.001 | 187 (59.7%) | 187 (59.7%) | 1 | | >4 | 559 (26.7%) | 134 (40.4%) | | 126 (40.3%) | 126 (40.3%) | | Depth of stromal invasion | | <½ | 668 (31.9%) | 57 (17.2%) | <0.001 | 53 (16.9%) | 53 (16.9%) | 1 | | ≥½ | 1427 (68.1%) | 275 (82.8%) | | 260 (83.1%) | 260 (83.1%) | | LVSI | | Negative | 1362 (65.0%) | 204 (61.4%) | 0.207 | 198 (63.3%) | 197 (62.9%) | 0.934 | | Positive | 733 (35.0%) | 128 (38.6%) | | 115 (36.7%) | 116 (37.1%) | | Parametrial invasion | | Negative | 2008 (95.8%) | 319 (96.1%) | 0.84 | 306 (97.8%) | 306 (97.8%) | 1 | | Positive | 87 (4.2%) | 13 (3.9%) | | 7 (2.2%) | 7 (2.2%) | | Vaginal margin invasion | | Negative | 2023 (96.6%) | 325 (97.9%) | 0.205 | 310 (99.0%) | 309 (98.7%) | 1 | | Positive | 72 (3.4%) | 7 (2.1%) | | 3 (1.0%) | 4 (1.3%) | | Pelvic lymph node metastasis | | Negative | 1688 (80.6%) | 239 (72.0%) | <0.001 | 227 (72.5%) | 227 (72.5%) | 1 | | Positive | 407 (19.4%) | 93 (28.0%) | | 86 (27.5%) | 86 (27.5%) | | Adjuvant therapy | | No | 643 (30.7%) | 59 (17.8%) | <0.001 | 55 (17.6%) | 55 (17.6%) | 1 | | Yes | 1452 (69.3%) | 273 (82.2%) | | 258 (82.4%) | 258 (82.4%) | | Preoperative SCC-Ag | | <6.5 ng/mL | 1588 (75.8%) | 226 (68.1%) | 0.003 | 218 (69.6%) | 218 (69.6%) | 1 | | ≥6.5 ng/Ml | 507 (24.2%) | 106 (31.9%) | | 95 (30.4%) | 95 (30.4%) |
|
|
PALND: para-aortic lymph node dissection; FIGO: International Federation of Gynecology and Obstetrics; LVSI: lymph-vascular space invasion; SCC-Ag: serum squamous cell carcinoma antigen.
|
